See more : Rinnai Corporation (5947.T) Income Statement Analysis – Financial Results
Complete financial analysis of The Greater Cannabis Company, Inc. (GCAN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of The Greater Cannabis Company, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- IST Limited (ISTLTD.BO) Income Statement Analysis – Financial Results
- CG Power and Industrial Solutions Limited (CGPOWER.BO) Income Statement Analysis – Financial Results
- Syncmold Enterprise Corp. (1582.TW) Income Statement Analysis – Financial Results
- Asahi Kagaku Kogyo Co.,Ltd. (7928.T) Income Statement Analysis – Financial Results
- Buxton Resources Limited (BUX.AX) Income Statement Analysis – Financial Results
The Greater Cannabis Company, Inc. (GCAN)
About The Greater Cannabis Company, Inc.
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company was founded in 2014 and is based in Baltimore, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 12.63K | 48.04K | 7.12K | 95.38K | 209.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.00K | 52.04K | 12.66K | 48.09K | 53.13K | 95.38K | 109.00 | 0.00 | 0.00 |
| Gross Profit | -5.00K | -52.04K | -25.00 | -46.00 | -46.01K | 0.00 | 100.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | -0.20% | -0.10% | -646.14% | 0.00% | 47.85% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 120.00K | 151.00K | 204.00K | 204.00K | 235.59K | 646.22K | 0.00 | 210.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 120.00K | 120.00K | 151.00K | 204.00K | 204.00K | 235.59K | 646.22K | 0.00 | 210.00 |
| Other Expenses | 50.36K | 57.04K | 192.12K | 90.41K | 205.57K | -592.91K | 0.00 | 100.00K | 0.00 |
| Operating Expenses | 170.36K | 177.04K | 343.12K | 294.41K | 409.57K | 286.14K | 646.22K | 100.00K | 210.00 |
| Cost & Expenses | 175.36K | 177.04K | 355.78K | 342.50K | 462.69K | 286.14K | 646.33K | 100.00K | 210.00 |
| Interest Income | 0.00 | 122.73 | 287.02 | 472.17K | 499.27 | 5.90K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.04K | 122.73K | 287.02K | 1.11M | 499.27K | 51.34K | 8.20K | 3.00K | -3.00K |
| Depreciation & Amortization | 5.00K | 5.00K | 5.00K | 4.58K | 20.00K | 10.25K | 52.52K | 22.82K | -6.00K |
| EBITDA | -170.36K | -232.54K | -310.21K | -289.87K | -1.13M | -777.48K | -765.46K | -100.00K | -6.21K |
| EBITDA Ratio | 0.00% | 0.00% | -5,681.55% | -2,204.87% | -10,612.35% | -804.74% | -309,148.33% | 0.00% | 0.00% |
| Operating Income | -175.36K | -177.04K | -343.15K | -294.46K | -525.32K | -190.92K | -646.12K | -100.00K | -210.00 |
| Operating Income Ratio | 0.00% | 0.00% | -2,716.91% | -612.89% | -7,378.13% | -200.18% | -309,148.33% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.04K | -183.23K | -259.08K | -656.71K | -1.12M | -648.15K | -147.45K | -3.00K | -3.00K |
| Income Before Tax | -188.40K | -360.27K | -602.23K | -951.17K | -1.65M | -839.07K | -793.57K | -103.00K | -3.21K |
| Income Before Tax Ratio | 0.00% | 0.00% | -4,768.22% | -1,979.79% | -23,154.42% | -879.76% | -379,697.13% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 183.23K | -92.42K | 1.63M | 499.27K | -596.81K | -44.31K | -22.82K | 0.00 |
| Net Income | -188.40K | -543.50K | -509.81K | -2.58M | -2.15M | -839.07K | -793.57K | -103.00K | -3.21K |
| Net Income Ratio | 0.00% | 0.00% | -4,036.49% | -5,367.39% | -30,166.59% | -879.76% | -379,697.13% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | -0.02 | -0.06 | -0.03 | -0.03 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.02 | -0.06 | -0.03 | -0.03 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 756.63M | 587.77M | 489.50M | 145.33M | 34.98M | 29.96M | 29.58M | 29.58M | 26.91M |
| Weighted Avg Shares Out (Dil) | 755.15M | 587.77M | 489.50M | 145.33M | 34.98M | 29.96M | 29.58M | 29.58M | 26.91M |
Meridian Wealth Management LLC Makes New Investment in InterContinental Hotels Group PLC (NYSE:IHG)
Meridian Wealth Management LLC bought a new position in InterContinental Hotels Group PLC (NYSE:IHG – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund...
Dimensional Fund Advisors LP Purchases 140,347 Shares of Tapestry, Inc. (NYSE:TPR)
Dimensional Fund Advisors LP increased its position in shares of Tapestry, Inc. (NYSE:TPR – Free Report) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,305,257 shares...
Koninklijke Philips (NYSE:PHG) Shares Sold by National Bank of Canada FI
National Bank of Canada FI cut its position in Koninklijke Philips (NYSE:PHG – Free Report) by 89.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,339...
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase...
GCANRx Featured in American Journal of Endocannabinoid Medicine
BALTIMORE, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics is pleased to announce that the Company and its scientific advisor, Dr....
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy
BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has entered into a licensing agreement...
GCANRx Announces Collaboration with Renowned Cannabis Research Lab
BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company ( OTCQB: GCAN ), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products is proud to announce a collaboration with Israel-based cannabis lab, Phytor LTD, a...
Source: https://incomestatements.info
Category: Stock Reports